Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03671811 · ClinicalTrials.gov registry record · Phase 2
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
A Phase 2 study of Endometrial Carcinoma and Atypical Endometrial Hyperplasia, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT03671811 is a Phase 2 study of Endometrial Carcinoma and Atypical Endometrial Hyperplasia that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 44 participants, below the 389-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03671811, a Phase 2 study of Endometrial Carcinoma and Atypical Endometrial Hyperplasia, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pterostilbene is an antioxidant found in blueberries or grapes, and it has been shown to be effective in killing tumor cells and reducing cancer burden. It is not yet known whether giving megestrol acetate with or without pterostilbene may work better in treating patients with endometrial cancer.
Conditions Studied
Interventions
- DRUG Megestrol Acetate
- BIOLOGICAL Pterostilbene
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-01-21 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03671811
The ClinicalTrials.gov registry entry for NCT03671811 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 389-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Endometrial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Megestrol Acetate is the first listed.
NCT03671811 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03671811 about?
NCT03671811 is a clinical study titled "Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy". This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cell...
What is the current status of trial NCT03671811?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2019-01-21. Estimated completion is 2026-03-30.
What conditions does trial NCT03671811 study?
This clinical trial studies the following conditions: Endometrial Carcinoma, Atypical Endometrial Hyperplasia.
What interventions are being tested in trial NCT03671811?
The interventions under investigation include: Megestrol Acetate (DRUG), Pterostilbene (BIOLOGICAL).
Who is sponsoring clinical trial NCT03671811?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03671811 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.